Literature DB >> 8884230

Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice.

R M Teixeira1, A R Santos, S J Ribeiro, J B Calixto, G A Rae, T C De Lima.   

Abstract

This study assessed the effects of intracerebroventricular administration of selective agonists and antagonists for tachykinin NK1 and NK2 receptors on performance of mice in the elevated plus-maze, an ethological model of anxiety. Mice were treated with either vehicle (5 microliters) or 1, 10, 100 or 500 pmol of substance P, neurokinin A, the selective NK1 receptor agonist substance P methyl ester, or the selective NK2 receptor agonist, [beta-Ala8]neurokinin A-(4-10). Other mice received similar doses of FK 888, i.e., N2-[(4R)-4-hydroxy-1-(1-methyl-1 H-indol-3-y)carbonyl-L-prolyl]-N-methyl-N-phenylmethyl-3-(2-naphthyl)-L- alaninamide, or SR 48968, i.e., (S)-N-methyl-(N-[4-acetylamine-4-phenylpiperidine)-2-(3, 4-dichlorophenyl)buthyl]benzamide, selective antagonists of tachykinin NK1 and NK2 receptors, respectively. Injections of substance P, neurokinin A, substance P methyl ester or [beta-Ala8]neurokinin A-(4-10) significantly reduced the frequency of open arm entries, and [beta-Ala8]neurokinin A-(4-10) also enhanced the percentage of entries into enclosed arms. Conversely, the NK1 antagonist FK 888 and the NK2 antagonist SR 48968 each increased the time spent in the open arms, and SR 48968 also increased the frequency of entries into the open arms. None of the tachykinin receptor agonists or antagonists modified motor performance and coordination on the rotarod apparatus or ambulation in an activity cage. Together, these results suggest that centrally administered NK1 and NK2 receptor agonists and antagonists can modulate anxiety, as evaluated in the elevated plus-maze test in mice. Stimulation of either tachykinin NK1 or NK2 receptors induces anxiogenic-like responses, whereas the reverse occurs following their blockade. The anxiolytic-like profiles of action of both tachykinin NK1 and NK2 receptor antagonists suggest that central tachykinin mechanisms are tonically involved in the modulation of anxiety.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8884230     DOI: 10.1016/0014-2999(96)00390-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  18 in total

Review 1.  Translational and reverse translational research on the role of stress in drug craving and relapse.

Authors:  Rajita Sinha; Yavin Shaham; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2011-04-15       Impact factor: 4.530

Review 2.  Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.

Authors:  Inga Herpfer; Klaus Lieb
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Neurokinin-1 receptors (NK1R:s), alcohol consumption, and alcohol reward in mice.

Authors:  Annika Thorsell; Jesse R Schank; Erick Singley; Stephen P Hunt; Markus Heilig
Journal:  Psychopharmacology (Berl)       Date:  2010-01-30       Impact factor: 4.530

4.  Evaluation of the anxiolytic-like effect of NKP608, a NK1-receptor antagonist, in two rat strains that differ in anxiety-related behaviors.

Authors:  Leandro F Vendruscolo; Reinaldo N Takahashi; Gustavo R Brüske; André Ramos
Journal:  Psychopharmacology (Berl)       Date:  2003-08-12       Impact factor: 4.530

Review 5.  Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues.

Authors:  Markus Heilig; Annika Thorsell; Wolfgang H Sommer; Anita C Hansson; Vijay A Ramchandani; David T George; Daniel Hommer; Christina S Barr
Journal:  Neurosci Biobehav Rev       Date:  2009-11-24       Impact factor: 8.989

6.  Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.

Authors:  Scott A Heldt; Michael Davis; Emiliangelo Ratti; Mauro Corsi; David Trist; Kerry J Ressler
Journal:  Behav Pharmacol       Date:  2009-10       Impact factor: 2.293

7.  Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test.

Authors:  Elaine C Gavioli; Giles A Rae; Girolamo Calo'; Remo Guerrini; Thereza C M De Lima
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 8.  Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression.

Authors:  Konstantinos A Paschos; Stavroula Veletza; Ekaterini Chatzaki
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

9.  Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats.

Authors:  Karl Ebner; Nadia M Rupniak; Alois Saria; Nicolas Singewald
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

10.  Pharmacological alterations of anxious behaviour in mice depending on both strain and the behavioural situation.

Authors:  Yan Clément; Anne-Marie Le Guisquet; Patrice Venault; Georges Chapouthier; Catherine Belzung
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.